Manufacturing news briefs — stories you might have missed

Arovella, Imugene progress drug combination trials ASX-listed companies Arovella Therapeutics and Imugene have announced a successful outcome from the initial in vitro experiments conducted as part of their research collaboration, and are progressing to the next phase of testing. According to a statement on Friday, results show that the combination of Arovella’s CAR19-iNKT cell therapy…